Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis

Zhang, 2010, Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis, Arthritis Rheum., 62, 2219, 10.1002/art.27510 Guler-Yuksel, 2009, Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis, Ann. Rheum. Dis., 68, 330, 10.1136/ard.2007.086348 Forslind, 2003, Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women, J. Rheumatol., 30, 2590 Rossini, 2011, Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis, J. Rheumatol., 38, 997, 10.3899/jrheum.100829 Rossini, 2016, Denosumab, cortical bone and bone erosions in rheumatoid arthritis, Ann. Rheum. Dis., 75, e70, 10.1136/annrheumdis-2016-210022 Rossini, 2017, Osteoporosis: an independent determinant of bone erosions in rheumatoid arthritis?, J. Bone Miner. Res., 32, 2142, 10.1002/jbmr.3209 Shim, 2018, Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications, Calcif. Tissue Int., 102, 533, 10.1007/s00223-017-0373-1 Kim, 2007, Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells, Biochem. Biophys. Res. Commun., 357, 1046, 10.1016/j.bbrc.2007.04.042 Takayanagi, 2009, Osteoimmunology and the effects of the immune system on bone, Nat. Rev. Rheumatol., 5, 667, 10.1038/nrrheum.2009.217 Takayanagi, 2000, T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma, Nature, 408, 600, 10.1038/35046102 Zaiss, 2007, Treg cells suppress osteoclast formation: a new link between the immune system and bone, Arthritis Rheum., 56, 4104, 10.1002/art.23138 Hengartner, 2013, IL-1beta inhibits human osteoblast migration, Mol. Med., 19, 36, 10.2119/molmed.2012.00058 Gilbert, 2002, Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha, J. Biol. Chem., 277, 2695, 10.1074/jbc.M106339200 Kotake, 2014, Effect of TNFalpha on osteoblastogenesis from mesenchymal stem cells, Biochim. Biophys. Acta, 1840, 1209, 10.1016/j.bbagen.2013.12.013 Kotake, 1996, Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation, J. Bone Miner. Res., 11, 88, 10.1002/jbmr.5650110113 Kotake, 1999, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J. Clin. Invest., 103, 1345, 10.1172/JCI5703 Lubberts, 2003, IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance, J. Immunol., 170, 2655, 10.4049/jimmunol.170.5.2655 Wei, 2005, IL-1 mediates TNF-induced osteoclastogenesis, J. Clin. Invest., 115, 282, 10.1172/JCI200523394 Walsh, 2018, Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity, Nat. Rev. Rheumatol., 14, 146, 10.1038/nrrheum.2017.213 McLean, 2009, Proinflammatory cytokines and osteoporosis, Curr. Osteoporos. Rep., 7, 134, 10.1007/s11914-009-0023-2 Tyagi, 2012, Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis, PLoS One, 7, 10.1371/journal.pone.0044552 Frenkel, 2010, Regulation of adult bone turnover by sex steroids, J. Cell. Physiol., 224, 305, 10.1002/jcp.22159 Rachon, 2002, Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women, J. Endocrinol., 172, 387, 10.1677/joe.0.1720387 Diarra, 2007, Dickkopf-1 is a master regulator of joint remodeling, Nat. Med., 13, 156, 10.1038/nm1538 Rossini, 2013, Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis, Calcif. Tissue Int., 93, 121, 10.1007/s00223-013-9749-z Wang, 2011, Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis, J. Rheumatol., 38, 821, 10.3899/jrheum.100089 Rossini, 2015, In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density, Clin. Exp. Rheumatol., 33, 77 Schett, 2008, The role of Wnt proteins in arthritis, Nat. Clin. Pract. Rheumatol., 4, 473, 10.1038/ncprheum0881 Heiland, 2010, Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression, Ann. Rheum. Dis., 69, 2152, 10.1136/ard.2010.132852 Adamopoulos, 2015, Alternative pathways of osteoclastogenesis in inflammatory arthritis, Nat. Rev. Rheumatol., 11, 189, 10.1038/nrrheum.2014.198 Boyesen, 2009, Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study, Arthritis Res. Ther., 11, R103, 10.1186/ar2749 Jensen, 2009, Comparison of dual X‐ray absorptiometry (DXA), digital X‐ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis, Scand. J. Rheumatol., 34, 27, 10.1080/03009740510017986 Haugeberg, 2004, Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50–70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study, Ann. Rheum. Dis., 63, 1331, 10.1136/ard.2003.015065 Krishnamurthy, 2016, Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, Ann. Rheum. Dis., 75, 721, 10.1136/annrheumdis-2015-208093 Chang, 2005, Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis, Rheumatology (Oxford), 44, 40, 10.1093/rheumatology/keh414 Foulquier, 2007, Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation, Arthritis Rheum., 56, 3541, 10.1002/art.22983 Kleyer, 2014, Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies, Ann. Rheum. Dis., 73, 854, 10.1136/annrheumdis-2012-202958 Bugatti, 2016, Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis, Arthritis Res. Ther., 18, 226, 10.1186/s13075-016-1116-9 Orsolini, 2017, Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients, Calcif. Tissue Int., 101, 17, 10.1007/s00223-017-0253-8 2019, Correction: identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, Ann. Rheum. Dis., 78, 866, 10.1136/annrheumdis-2015-208093corr1 Toes, 2019, Pathogenic effector functions of ACPA: where do we stand?, Ann. Rheum. Dis., 78, 716, 10.1136/annrheumdis-2019-215337 Kuchuk, 2009, Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective, J. Bone Miner. Res., 24, 693, 10.1359/jbmr.081209 Rossini, 2010, Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability, Arthritis Res. Ther., 12, R216, 10.1186/ar3195 Lin, 2016, Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis, PLoS One, 11, 10.1371/journal.pone.0146351 Patel, 2007, Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis, Arthritis Rheum., 56, 2143, 10.1002/art.22722 Franco, 2017, Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: a systematic review and meta-analysis, Medicine (Baltimore), 96, e7024, 10.1097/MD.0000000000007024 Chandrashekara, 2017, Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: an exploratory study, Int. J. Rheum. Dis., 20, 825, 10.1111/1756-185X.12770 Adami, 2018, An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis, Mod. Rheumatol., 1, 10.1080/14397595.2018.1532622 Fassio, 2017, In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls, Clin. Rheumatol., 36, 2377, 10.1007/s10067-017-3734-2 Orsolini, 2018, Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis, Clin. Rheumatol., 37, 3093, 10.1007/s10067-018-4205-0 Gao, 2008, T cells potentiate PTH-induced cortical bone loss through CD40L signaling, Cell Metab., 8, 132, 10.1016/j.cmet.2008.07.001 Lange, 2005, Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study, Rheumatology (Oxford), 44, 1546, 10.1093/rheumatology/kei082 Eekman, 2011, Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis, Ann. Rheum. Dis., 70, 389, 10.1136/ard.2009.127787 Dischereit, 2013, Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study, Clin. Rheumatol., 32, 377, 10.1007/s10067-012-2128-8 Toussirot, 2017, Eur. J. Rheumatol., 4, 189, 10.5152/eurjrheum.2017.17006 Vis, 2006, Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis, Ann. Rheum. Dis., 65, 1495, 10.1136/ard.2005.044198 Vis, 2003, Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab, Arthritis Rheum., 48, 2996, 10.1002/art.11292 Marotte, 2007, A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab, Arthritis Res. Ther., 9, R61, 10.1186/ar2219 Seriolo, 2006, Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis, Ann. N. Y. Acad. Sci., 1069, 420, 10.1196/annals.1351.040 Chopin, 2008, Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis, Ann. Rheum. Dis., 67, 353, 10.1136/ard.2007.076604 Guler-Yuksel, 2008, Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis, Ann. Rheum. Dis., 67, 823, 10.1136/ard.2007.073817 Okano, 2014, The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid, J. Bone Miner. Metab., 32, 593, 10.1007/s00774-013-0535-9 Krieckaert, 2013, Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study, Rheumatology (Oxford), 52, 547, 10.1093/rheumatology/kes320 Szentpetery, 2013, Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis, J. Rheumatol., 40, 653, 10.3899/jrheum.120397 Haugeberg, 2009, Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study, Ann. Rheum. Dis., 68, 1898, 10.1136/ard.2008.106484 Orsolini, 2016, Short-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritis, Calcif. Tissue Int., 98, 580, 10.1007/s00223-016-0114-x Haugeberg, 2014, Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era, BMC Musculoskelet. Disord., 15, 289, 10.1186/1471-2474-15-289 Gough, 1994, Generalised bone loss in patients with early rheumatoid arthritis, Lancet, 344, 23, 10.1016/S0140-6736(94)91049-9 Siu, 2015, Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials, Arthritis Care Res. (Hoboken), 67, 754, 10.1002/acr.22519 Haugeberg, 2005, Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial, Arch. Intern. Med., 165, 1293, 10.1001/archinte.165.11.1293 Engvall, 2008, Better Anti-Rheumatic Farmac OTSG. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study, Arthritis Res. Ther., 10, R128, 10.1186/ar2542 Habib, 2005, Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids, Clin. Rheumatol., 24, 129, 10.1007/s10067-004-0989-1 Baim, 2005, Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry, J. Clin. Densitom., 8, 371, 10.1385/JCD:8:4:371 Kanis, 2018, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos. Int., 30, 3, 10.1007/s00198-018-4704-5 Yasunori, 2008, Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis, Clin. Rheumatol., 27, 1093, 10.1007/s10067-008-0870-8 Fassio, 2018, Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators, Int. Immunopharmacol., 67, 487, 10.1016/j.intimp.2018.12.050 Torikai, 2006, The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis, Rheumatology (Oxford), 45, 761, 10.1093/rheumatology/kei280 Gengenbacher, 2008, Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis, Ann. Rheum. Dis., 67, 620, 10.1136/ard.2007.076711 Adami, 2016, Effects of TNF inhibitors on parathyroid hormone and wnt signaling antagonists in rheumatoid arthritis, Calcif. Tissue Int., 99, 360, 10.1007/s00223-016-0161-3 Ziolkowska, 2002, High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment, Arthritis Rheum., 46, 1744, 10.1002/art.10388 Schett, 2012, Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment, Nat. Rev. Rheumatol., 8, 656, 10.1038/nrrheum.2012.153 Fassio, 2017, New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application, Curr. Pharm. Des., 23, 6241, 10.2174/1381612823666170713104431 Kawai, 2012, Effects of anti-tumor necrosis factor alpha agents on bone, Curr. Opin. Rheumatol., 24, 576, 10.1097/BOR.0b013e328356d212 Kim, 2012, Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study, J. Bone Miner. Res., 27, 789, 10.1002/jbmr.1489 Coulson, 2009, Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry, J. Clin. Rheumatol., 15, 155, 10.1097/RHU.0b013e3181a5679d Vis, 2005, Bone mineral density in patients with rheumatoid arthritis treated with infliximab, Ann. Rheum. Dis., 64, 336, 10.1136/ard.2003.017780 Korczowska, 2013, Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients, Yonsei Med. J., 54, 183, 10.3349/ymj.2013.54.1.183 Suzuki, 2018, Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis, Ther. Clin. Risk Manag., 14, 453, 10.2147/TCRM.S156350 Naka, 2002, The paradigm of IL-6: from basic science to medicine, Arthritis Res., 4, S233, 10.1186/ar565 Kwan Tat, 2004, IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology, Cytokine Growth Factor Rev., 15, 49, 10.1016/j.cytogfr.2003.10.005 Wong, 2006, Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis, Arthritis Rheum., 54, 158, 10.1002/art.21537 Tanaka, 2014, Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model, Clin. Exp. Immunol., 175, 172, 10.1111/cei.12201 Kato, 2008, Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model, Exp. Mol. Pathol., 84, 262, 10.1016/j.yexmp.2008.03.003 Malysheva, 2016, Interleukin 6/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts, Croat. Med. J., 57, 89, 10.3325/cmj.2016.57.89 Garnero, 2010, Arthritis Rheum., 62, 33, 10.1002/art.25053 Karsdal, 2012, IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522), Semin. Arthritis Rheum., 42, 131, 10.1016/j.semarthrit.2012.01.004 Kanbe, 2012, Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis, Rheumatol. Int., 32, 2669, 10.1007/s00296-011-2021-9 Chen, 2017, Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis, PLoS One, 12, 10.1371/journal.pone.0188454 Bay-Jensen, 2014, Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study, Semin. Arthritis Rheum., 43, 470, 10.1016/j.semarthrit.2013.07.008 Briot, 2015, The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis, Joint Bone Spine, 82, 109, 10.1016/j.jbspin.2014.10.015 Boyapati, 2016, Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY, Arthritis Res. Ther., 18, 225, 10.1186/s13075-016-1132-9 Terpos, 2011, Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis, Clin. Exp. Rheumatol., 29, 921 Gabay, 2017, FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study, Ann. Rheum. Dis., 76, 570- Kume, 2014, The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis, Rheumatology (Oxford), 53, 900, 10.1093/rheumatology/ket468 Abu-Shakra, 2018, Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis, Isr. Med. Assoc. J., 20, 239 Kremer, 2003, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig, N. Engl. J. Med., 349, 1907, 10.1056/NEJMoa035075 Axmann, 2008, CTLA-4 directly inhibits osteoclast formation, Ann. Rheum. Dis., 67, 1603, 10.1136/ard.2007.080713 Bozec, 2014, T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway, Sci. Transl. Med., 6, 10.1126/scitranslmed.3007764 Kliwinski, 2005, Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis, J. Autoimmun., 25, 165, 10.1016/j.jaut.2005.09.020 Bedi, 2010, Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss, Ann. N. Y. Acad. Sci., 1192, 215, 10.1111/j.1749-6632.2009.05216.x Roser-Page, 2018, CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin, Ann. N. Y. Acad. Sci., 1415, 21, 10.1111/nyas.13643 Roser-Page, 2018, Neutralization of CD40 ligand costimulation promotes bone formation and accretion of vertebral bone mass in mice, Rheumatology (Oxford), 57, 1105, 10.1093/rheumatology/kex525 Tada, 2018, Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study, Rheumatol. Int., 38, 777, 10.1007/s00296-017-3922-z Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N. Engl. J. Med., 350, 2572, 10.1056/NEJMoa032534 Yeo, 2011, Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis, Ann. Rheum. Dis., 70, 2022, 10.1136/ard.2011.153312 Onal, 2012, Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss, J. Biol. Chem., 287, 29851, 10.1074/jbc.M112.377945 Wheater, 2011, Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis, Osteoporos. Int., 22, 3067, 10.1007/s00198-011-1607-0 Hein, 2011, Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study, Rheumatol. Int., 31, 269, 10.1007/s00296-010-1560-9 Boumans, 2012, Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis, Ann. Rheum. Dis., 71, 108, 10.1136/annrheumdis-2011-200198 Wheater, 2018, Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study, PLoS One, 13, 10.1371/journal.pone.0201527 Salvin, 2010, Variations in lumbar spine and femoral BMD after rituximab therapy in active rheumatoid arthritis, Ann. Rheum. Dis., 69, 714 Meyer, 2010, Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis, J. Inflamm. (Lond.), 7, 41, 10.1186/1476-9255-7-41 O’Shea, 2015, The JAK-STAT pathway: impact on human disease and therapeutic intervention, Annu. Rev. Med., 66, 311, 10.1146/annurev-med-051113-024537 Chen, 2010, Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians, J. Bone Miner. Res., 25, 339, 10.1359/jbmr.090724 Minegishi, 2009, Hyper-IgE syndrome, Curr. Opin. Immunol., 21, 487, 10.1016/j.coi.2009.07.013 Zhou, 2011, Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species, Bone, 49, 404, 10.1016/j.bone.2011.04.020 Vidal, 2018, Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model, Rheumatology (Oxford), 57, 1461, 10.1093/rheumatology/kex258 LaBranche, 2012, JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production, Arthritis Rheum., 64, 3531, 10.1002/art.34649 Murakami, 2017, A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro, PLoS One, 12, 10.1371/journal.pone.0181126